Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537429 · ClinicalTrials.gov registry record · Phase 1
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04537429 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 28 participants.
The verdict
NCT04537429, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
Interventions
- DRUG Eptinezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537429
The ClinicalTrials.gov registry entry for NCT04537429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eptinezumab is the first listed.
NCT04537429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04537429 about?
NCT04537429 is a clinical study titled "A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab". The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
What is the current status of trial NCT04537429?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-08-04. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT04537429?
The interventions under investigation include: Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT04537429?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.